By Susanna Moon
Chicago, Jan. 25 – Moberg Pharma AB said it will issue a SEK 300 million five-year senior unsecured bond loan.
Interest on the loan will be Stibor plus 600 basis points and have a total framework amount of SEK 600 million, according to a company news release.
Moberg Pharma said it plans to make significant investments during 2016, focusing on strengthening brand platforms for the company’s strategic brands in the United States, increased international distribution, acquiring additional brands and initiating phase 3 studies for MOB-015.
Carnegie Investment Bank and Swedbank are the financial advisers. Gernandt & Danielsson is the legal adviser.
Moberg said it plans to apply to list the bond loan on Nasdaq Stockholm within 30 days.
Moberg Pharma is a Bromma, Sweden-based pharmaceutical company.
| Issuer: | Moberg Pharma AB
|
| Issue: | Senior unsecured bond loan
|
| Amount: | SEK 300 million
|
| Maturity: | Jan. 29, 2021
|
| Coupon: | Stibor plus 600 bps
|
| Warrants: | No
|
| Announcement date: | Jan. 25
|
| Stock symbol: | STO: MOB
|
| Stock price: | SEK 56.00 at close Jan. 24
|
| Market capitalization: | SEK 34.34 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
